Literature DB >> 19603508

A Cre/LoxP conditional luciferase reporter transgenic mouse for bioluminescence monitoring of tumorigenesis.

Steve Woolfenden1, Haihao Zhu, Al Charest.   

Abstract

Genetically engineered, Cre/LoxP-conditional mouse models of cancer are designed to investigate the genetic contributors of tumorigenesis and are well suited to assess therapeutic treatment responses. The capacity to serially visualize tumor burden in a noninvasive fashion would greatly strengthen their applications. We report the generation of a bioluminescent reporter strain that allows monitoring of tumor development in preexisting conditional mouse tumor models. We demonstrate that, in a Cre-dependent glioblastoma multiforme model, tumor initiation and progression is readily monitored over time and that luminescent output is related to tumor volume. Our results show that this reporter strain may be combined with various Cre/loxP mouse tumor models to allow for noninvasive longitudinal monitoring of tumor growth and therapeutic response in vivo. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19603508     DOI: 10.1002/dvg.20545

Source DB:  PubMed          Journal:  Genesis        ISSN: 1526-954X            Impact factor:   2.487


  8 in total

1.  The novel Hsp90 inhibitor NXD30001 induces tumor regression in a genetically engineered mouse model of glioblastoma multiforme.

Authors:  Haihao Zhu; Steve Woolfenden; Roderick T Bronson; Zahara M Jaffer; Sofia Barluenga; Nicolas Winssinger; Allan E Rubenstein; Ruihong Chen; Al Charest
Journal:  Mol Cancer Ther       Date:  2010-07-19       Impact factor: 6.261

2.  PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.

Authors:  Helen Y Zou; Qiuhua Li; Lars D Engstrom; Melissa West; Vicky Appleman; Katy A Wong; Michele McTigue; Ya-Li Deng; Wei Liu; Alexei Brooun; Sergei Timofeevski; Scott R P McDonnell; Ping Jiang; Matthew D Falk; Patrick B Lappin; Timothy Affolter; Tim Nichols; Wenyue Hu; Justine Lam; Ted W Johnson; Tod Smeal; Al Charest; Valeria R Fantin
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-02       Impact factor: 11.205

3.  Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression.

Authors:  Alan T Yeo; Shruti Rawal; Bethany Delcuze; Anthos Christofides; Agata Atayde; Laura Strauss; Leonora Balaj; Vaughn A Rogers; Erik J Uhlmann; Hemant Varma; Bob S Carter; Vassiliki A Boussiotis; Al Charest
Journal:  Nat Immunol       Date:  2022-05-27       Impact factor: 31.250

4.  Overexpression of miR-155 in the liver of transgenic mice alters the expression profiling of hepatic genes associated with lipid metabolism.

Authors:  Xiaolin Lin; Junshuang Jia; Tao Du; Wei Li; Xiaoyan Wang; Jieqiong Wei; Xia Lin; Hui Zeng; Longping Yao; Xuebing Chen; Jingshen Zhuang; Jie Weng; Yu Liu; Jihong Lin; Qinghong Wu; Wanshan Wang; Kaitai Yao; Kang Xu; Dong Xiao
Journal:  PLoS One       Date:  2015-03-23       Impact factor: 3.240

5.  Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme.

Authors:  H J Jun; J Acquaviva; D Chi; J Lessard; H Zhu; S Woolfenden; R T Bronson; R Pfannl; F White; D E Housman; L Iyer; C A Whittaker; A Boskovitz; A Raval; A Charest
Journal:  Oncogene       Date:  2011-10-24       Impact factor: 9.867

Review 6.  Lineage-tracing methods and the kidney.

Authors:  Benjamin D Humphreys; Derek P DiRocco
Journal:  Kidney Int       Date:  2013-10-02       Impact factor: 10.612

Review 7.  Adult stem cell lineage tracing and deep tissue imaging.

Authors:  Juergen Fink; Amanda Andersson-Rolf; Bon-Kyoung Koo
Journal:  BMB Rep       Date:  2015-12       Impact factor: 4.778

Review 8.  Imaging Cancer Metabolism.

Authors:  Milica Momcilovic; David B Shackelford
Journal:  Biomol Ther (Seoul)       Date:  2018-01-01       Impact factor: 4.634

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.